Skip to main content
RocheLaunch

Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesothelioma

Source: Autobound Signal API · 87 signals tracked for Roche · updated

Get Roche's live signals in Claude or ChatGPT, or by API

AskWhat changed at Roche this week? Use Autobound signals for roche.com.

What happened

Roche has launched the VENTANA BAP1 (SP527) test, an automated immunohistochemistry diagnostic assay to identify mesothelioma.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Basel, 28 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the global launch of the VENTANA BAP1 (SP527)* test. This automated, ready-to-use immunohistochemistry (IHC) assay provides a reliable, highly specific diagnostic tool to help clinicians and pathologists accurately identify mesothelioma and distinguish it from other malignancies, including non-small cell lung cancer (NSCLC). The BAP1 assay is registered as a Class I IVD with U.S. Food and Drug Administration, has received IVDR approval as a Class C device, and is available globally.

globenewswire.com/news-release/2026/10/28/3389862/0/en/roche-strength...Read the full source

Extracted by Autobound

From the Signal API record
Event
Launch

What this signalsA launch often needs new go-to-market and support spend.

Product
VENTANA BAP1 (SP527)
Takes effect
Oct 28, 2026
Location
Basel, Basel-City, Switzerland

More launch signals at other companies

The full record

From the Signal API record

Details

Ticker
SIX:RO

Topics and mentions

Product tags

  • general technology
  • medical

Extraction

Confidence
95%
Detected
Oct 28, 2026
signal_type
news
signal_subtype
launches

Use this data

Get every launch signal for Roche and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Roche this week?”

  2. Send it to your own tools

    The Signal API returns launch signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/4ce3a29f-3496-863d-aad5-5c2d608377bb returns this record as JSON. POST /v1/companies/enrich returns every signal for roche.com.

{
  "signal_id": "4ce3a29f-3496-863d-aad5-5c2d608377bb",
  "signal_type": "news",
  "signal_subtype": "launches",
  "detected_at": "2026-10-28T06:00:00+00:00",
  "company": {
    "name": "Roche",
    "domain": "roche.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/10/28/3389862/0/en/roche-strengthens-cancer-diagnostic-portfolio-with-launch-of-test-for-differential-diagnosis-of-mesothelioma.html",
    "title": "Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesothelioma",
    "ticker": "SIX:RO",
    "excerpt": "Basel, 28 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the global launch of the VENTANA BAP1 (SP527)* test. This automated, ready-to-use immunohistochemistry (IHC) assay provides a reliable, highly specific diagnostic tool to help clinicians and pathologists accurately identify mesothelioma and distinguish it from other malignancies, including non-small cell lung cancer (NSCLC). The BAP1 assay is registered as a Class I IVD with U.S. Food and Drug Administration, has received IVDR approval as a Class C device, and is available globally.",
    "product": "VENTANA BAP1 (SP527)",
    "summary": "Roche has launched the VENTANA BAP1 (SP527) test, an automated immunohistochemistry diagnostic assay to identify mesothelioma.",
    "location": "Basel, Switzerland",
    "planning": false,
    "confidence": 0.95,
    "product_data": {
      "name": "VENTANA BAP1 (SP527)",
      "full_text": "VENTANA BAP1 (SP527)* test",
      "fuzzy_match": false
    },
    "product_tags": [
      "general_technology",
      "medical"
    ],
    "published_at": "2026-10-28T06:00:00Z",
    "location_data": [
      {
        "city": "Basel",
        "state": "Basel-City",
        "region": "Western Europe",
        "country": "Switzerland",
        "continent": "Europe",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-10-28",
    "article_sentence": "Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the global launch of the VENTANA BAP1 (SP527)* test."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.